JUNSHI BIO(01877.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at loss of CNY 20.56 million, loss narrowed by 91.24% YoY
NewTimeSpace News: April 27, 2026, JUNSHI BIO(01877.HK) released its Q1 Report for the period ended December 31, 2026, Total Revenue stood at CNY 726.29 million, increased by 45.09% YoY; Net Profit stood at loss of CNY 43.43 million, loss narrowed by 83.27% YoY; Profit Attributable to Shareholders stood at loss of CNY 20.56 million, loss narrowed by 91.24% YoY; Basic Earnings Per Share (EPS) stood at loss of CNY cents 2.
In terms of profitability, JUNSHI BIO Gross Profit changed from CNY 406.69 million in the same period last year to CNY 579.31 million in the current period, increased by CNY 172.62 million; gross profit margin changed from 81.24% in the same period last year to 79.76% in the current period, decreased by 1.48 percentage points; net profit changed from loss of CNY 259.59 million in the same period last year to loss of CNY 43.43 million in the current period, increased by CNY 216.16 million; net profit margin changed from -51.86% in the same period last year to -5.98% in the current period, increased by 45.88 percentage points.
In terms of earnings quality, JUNSHI BIO Operating Profit changed from loss of CNY 281.72 million in the same period last year to loss of CNY 28.59 million in the current period, increased by CNY 253.13 million; Operating Profit Margin changed from -56.28% in the same period last year to -3.94% in the current period, increased by 52.34 percentage points; Net Cash Flow from Operating Activities changed from cash outflow of CNY 24.33 million in the same period last year to cash inflow of CNY 57.85 million in the current period, increased by CNY 82.18 million; Ratio of Net Cash Flow from Operating Activities to Total Operating Revenue changed from -4.86% in the same period last year to 7.97% in the current period, increased by 12.83 percentage points.
In terms of financial soundness, JUNSHI BIO Debt-to-Asset Ratio changed from 47.98% in the same period last year to 56.97% in the current period, increased by 8.99 percentage points; Total Equity changed from CNY 5.669 billion in the same period last year to CNY 6.09 billion in the current period, increased by CNY 420.95 million; Cash and Cash Equivalents changed from CNY 2.507 billion in the same period last year to CNY 3.891 billion in the current period, increased by CNY 1.38 billion; Current Liabilities changed from CNY 3.04 billion in the same period last year to CNY 2.75 billion in the current period, decreased by CNY 298.39 million; Quick Ratio changed from 1.2 in the same period last year to 1.93 in the current period, increased by 0.73 percentage points.
In terms of R&D investment focus, JUNSHI BIO R&D Expenses changed from CNY 350.58 million in the same period last year to CNY 282.5 million in the current period, decreased by CNY 68.08 million; R&D to Total Revenue Ratio changed from 70.03% in the same period last year to 38.9% in the current period, decreased by 31.13 percentage points.
By the close of trading on April 27, 2026, JUNSHI BIO(01877) saw a gain of 0.77% in its share price, closing at HKD 26.08. The full-day turnover stood at HKD 137.3 million, with the latest market capitalization at HKD 6.79 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
